J&J (JNJ) Cuts Diagnostic Unit Bidders to Three Groups
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $258.51 +1.51%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.1%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.1%
Join SI Premium – FREE
In Johnson & Johnson's (NYSE: JNJ) effort to unload its diagnostics unit, the company is said to have whittled potential buyers down to just three.
Bloomberg reports Friday that J&J's list for its Ortho Clinical Diagnostics unit include a joint bid from Blackstone Group (NYSE: BX)/Danaher (NYSE: DHR), joint bid from Leonard Green/CVC Capital, and a solo bid from private equity giant Carlyle group (Nasdaq: CG).
J&J is expected to make a decision on the unit before the end of 2013, according to sources familiar with the matter. JPMorgan was tapped to advise J&J on the sale.
J&J shares are indicated lower Friday.
Bloomberg reports Friday that J&J's list for its Ortho Clinical Diagnostics unit include a joint bid from Blackstone Group (NYSE: BX)/Danaher (NYSE: DHR), joint bid from Leonard Green/CVC Capital, and a solo bid from private equity giant Carlyle group (Nasdaq: CG).
J&J is expected to make a decision on the unit before the end of 2013, according to sources familiar with the matter. JPMorgan was tapped to advise J&J on the sale.
J&J shares are indicated lower Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
- Rhinebeck Bancorp stockholders approve mutual-to-stock conversion
- Orvana buys adjacent Argentina claims for $1.2M, expanding Taguas
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and Acquisitions, RumorsRelated Entities
JPMorgan, The Carlyle Group, CVC Capital PartnersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
